<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395601</url>
  </required_header>
  <id_info>
    <org_study_id>1205-01</org_study_id>
    <nct_id>NCT02395601</nct_id>
  </id_info>
  <brief_title>A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas</brief_title>
  <official_title>A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Constellation Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Constellation Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in&#xD;
      patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Dose-limiting toxicities (DLTs)</measure>
    <time_frame>DLTs asessed during Cycle 1 (first 28 days on study)</time_frame>
    <description>Frequency of dose-limiting toxicities (DLTs) associated with CPI-1205 administration during the first cycle (first 28 days) of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Assessed from Day 1 of Cycle 1 through 30 days after patient's last dose of study drug</time_frame>
    <description>Safety and tolerability of CPI-1205 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, and ECOG score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of CPI-1205: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F</measure>
    <time_frame>Assessed during cycle 1 (first 28 days on study); and on cycle 2, day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of CPI-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3; changes in the expression of genes whose transcription may be altered by EZH2 inhibition</measure>
    <time_frame>Assessed during cycle 1 (first 28 days on study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of CPI-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3 (H3K27me3)</measure>
    <time_frame>Assessed during cycle 1 (first 28 days on study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response assessment will be performed using the 2014 Lugano Response Criteria for Hodgkin and Non-Hodgkin Lymphoma</measure>
    <time_frame>After every 2 cycles of treatment for the first 6 cycles, and after every 4 cycles thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CPI-1205</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-1205</intervention_name>
    <description>Small molecule inhibitor of the enzyme EZH2</description>
    <arm_group_label>CPI-1205</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adults (aged ≥ 18 years)&#xD;
&#xD;
        Histologically confirmed diagnosis of a B-cell lymphoma that has progressed in spite of&#xD;
        prior treatment, and for which additional effective standard therapy is not available&#xD;
&#xD;
        Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
        Adequate hematological, renal, hepatic, and coagulation laboratory assessments&#xD;
&#xD;
        Must give written informed consent to participate in this study before the performance of&#xD;
        any study-related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A primary lymphoma of the central nervous system (CNS) or known lymphomatous involvement of&#xD;
        the CNS&#xD;
&#xD;
        Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the&#xD;
        absorption of CPI-1205, including any unresolved nausea, vomiting, or diarrhea that is&#xD;
        CTCAE grade &gt;1&#xD;
&#xD;
        Treatment with proton pump inhibitors, H2 antagonists, or antacids&#xD;
&#xD;
        Achlorhydria, either documented or suspected on the basis of an associated disease (e.g.,&#xD;
        pernicious anemia, atrophic gastritis, or certain gastric surgical procedures)&#xD;
&#xD;
        Impaired cardiac function or clinically significant cardiac diseases, including any of the&#xD;
        following:&#xD;
&#xD;
          -  Acute myocardial infarction or angina pectoris ≤ 6 months prior to starting study drug&#xD;
&#xD;
          -  New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
          -  QTcF &gt; 470 msec on the screening ECG&#xD;
&#xD;
        Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not&#xD;
        excluded)&#xD;
&#xD;
        A past medical history of other clinically significant cardiovascular disease (e.g.,&#xD;
        uncontrolled hypertension, history of labile hypertension or history of poor compliance&#xD;
        with an antihypertensive regimen)&#xD;
&#xD;
        Any other concurrent severe and/or uncontrolled concomitant medical condition that could&#xD;
        compromise participation in the study (e.g., clinically significant pulmonary disease,&#xD;
        clinically significant neurological disorder, active or uncontrolled infection)&#xD;
&#xD;
        Systemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of&#xD;
        CPI 1205&#xD;
&#xD;
        Radioimmunotherapy (e.g., 131I-tositumomab, 90Y-ibritumomab tiuxetan) less than 6 weeks&#xD;
        before the first dose of CPI-1205&#xD;
&#xD;
        Treatment with an investigational small molecule less than 2 weeks before the first dose of&#xD;
        CPI-1205.&#xD;
&#xD;
        Treatment with a therapeutic antibody less than 4 weeks before the first dose of CPI-1205.&#xD;
&#xD;
        Treatment with medications that are strong inhibitors of CYP3A4&#xD;
&#xD;
        Treatment with medications that are inducers of CYP3A4 enzymes&#xD;
&#xD;
        Treatment with medications that are known to carry a risk of Torsades de Pointes&#xD;
&#xD;
        Pregnant or lactating women&#xD;
&#xD;
        Women of child bearing potential and men with reproductive potential, if they are unwilling&#xD;
        to use adequate contraception while on study therapy and for 3 months thereafter&#xD;
&#xD;
        Patients unwilling or unable to comply with this study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debbie Johnson</last_name>
    <role>Study Director</role>
    <affiliation>Constellation Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-Cell Lymphoma</keyword>
  <keyword>EZH2 Inhibitor</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

